ANALYTICAL METHOD FOR INLINE PLUTONIUM ANALYSES

Laboratory studies demonstrated the feasibility of a colorimetric method for the in-line analysis of plutonium(III) and plutonium(IV) in the Purex process. Negligible interference was caused by normal variations in the concentration of nitric acid, nitrous acid, or ferric sulfate. (auth

CSM Testbed Development and Large-Scale Structural Applications

A research activity called Computational Structural Mechanics (CSM) conducted at the NASA Langley Research Center is described. This activity is developing advanced structural analysis and computational methods that exploit high-performance computers. Methods are developed in the framework of the CSM Testbed software system and applied to representative complex structural analysis problems from the aerospace industry. An overview of the CSM Testbed methods development environment is presented and some new numerical methods developed on a CRAY-2 are described. Selected application studies performed on the NAS CRAY-2 are also summarized

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.

BackgroundThis retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in order to explore the concept of clonal evolution by evaluating the impact of prior activity and intervening time interval.MethodsEighty-nine KRAS exon 2-wild-type metastatic colorectal patients were retreated on phase I/II clinical trials containing anti-EGFR therapies after progressing on prior cetuximab or panitumumab. Response on prior anti-EGFR therapy was defined retrospectively per physician-records as response or stable disease ≥6 months. Multivariable statistical methods included a multiple logistic regression model for response, and Cox proportional hazards model for progression-free survival.ResultsRetreatment anti-EGFR agents were cetuximab (n = 76) or cetuximab plus erlotinib (n = 13). The median interval time between prior and retreatment regimens was 4.57 months (range: 0.46-58.7). Patients who responded to the prior cetuximab or panitumumab were more likely to obtain clinical benefit to the retreatment compared to the non-responders in both univariate (p = 0.007) and multivariate analyses (OR: 3.38, 95 % CI: 1.27, 9.31, p = 0.019). The clinical benefit rate on retreatment also showed a marginally significant association with interval time between the two anti-EGFR based therapies (p = 0.053). Median progression-free survival on retreatment was increased in prior responders (4.9 months, 95 % CI: 3.6, 6.2) compared to prior non-responders (2.5 months, 95 % CI, 1.58, 3.42) in univariate (p = 0.064) and multivariate analysis (HR: 0.70, 95 % CI: 0.43-1.15, p = 0.156).ConclusionOur data lends support to the concept of clonal evolution, though the clinical impact appears less robust than previously reported. Further work to determine which patients benefit from retreatment post progression is needed

Enacting accountability under populist pressures: theorizing the relationship between anti-elite rhetoric and public accountability

While populism challenges the pluralism and technocratic expertise on which public bureaucracies are based, extant scholarship has overlooked its effects on accountability processes. In particular, it neglects the impact of anti-elite rhetoric, characterized by what can be regarded as “emotionalized blame attribution,” on the thinking and behavior of accountability actors. Responding to this gap, this article examines the impact of this distinctive form of populist rhetoric on accountability relationships within the bureaucratic state. It identifies three “stages” whereby these populist pressures challenge accountability relationships, threaten the reputation of accountability actors, and result in alternative accountability practices. In doing so, the article provides a roadmap for assessing the impact of anti-elite rhetoric on accountability actions

Could Public Restrooms Be an Environment for Bacterial Resistomes?

PMCID: PMC3547874This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited